Persistence and Clearance of HPV From the Penis of Men Infected and Non-Infected With HIV
Carregando...
Citações na Scopus
18
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-LISS
Autores
Citação
JOURNAL OF MEDICAL VIROLOGY, v.83, n.1, p.127-131, 2011
Resumo
Due to high rates of human papillomavirus (HPV) infection, the incidence of intraepithelial neoplasia and anal cancer, most studies concerning HPV in men seropositive for HIV have focused on the anal canal. Few studies have targeted the penile region in HIV-infected men. A total of 72 men seropositive for HIV and 72 men seronegative for HIV were followed-up for 6 months, and their penile exfoliated cells were tested for HPV DNA. There were no significant differences between the HIV-positive and HIV-negative men in persistence (respectively, 69.5% vs. 66.9%), clearance (respectively, 15.3% vs. 23.1%), and those men never infected with HPV during the four follow-up visits (15.2% for HIV-positive vs. 20% for HIV-negative). High-risk HPV types were detected more frequently in penile smears from men infected with HIV, while, in HIV-seronegative men, the low-risk HPV types were more abundant (P=0.001). Multiple infections with both high- and low-risk HPV types were significantly more frequent in HIV-seropositive compared to those who were HIV-seronegative (P=0.0004). The attendance rates at follow-up visits were 86%, 78%, and 58% in months 1, 2, and 6, respectively, for men infected with HIV and 93%, 72%, and 60% for the HIV-negative group. It is concluded that HIV infection can be considered a risk factor for clearance and persistence of HPV. Multiple infections with different types of HPV including high-risk HPVs are frequent in men who are infected with HIV. J. Med. Virol. 83:127-131, 2011. (C) 2010 Wiley-Liss, Inc.
Palavras-chave
human papillomavirus (HPV), men, HIV infection, persistence and clearance
Referências
- VANDOORNUM GJJ, 1994, GENITOURIN MED, V70, P240
- Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
- Wikstrom A, 2000, INT J STD AIDS, V11, P80
- Kjaer SK, 2005, CANCER EPIDEM BIOMAR, V14, P1528, DOI 10.1158/1055-9965.EPI-04-0754
- Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903
- Frazer IH, 2009, VIROLOGY, V384, P410, DOI 10.1016/j.virol.2008.10.004
- Palefsky JM, 1998, AIDS, V12, P495, DOI 10.1097/00002030-199805000-00011
- Gravitt PE, 1998, J CLIN MICROBIOL, V36, P3020
- Aboulafia DM, 2001, CANCER INVEST, V19, P266, DOI 10.1081/CNV-100102554
- Levi JE, 2002, J CLIN MICROBIOL, V40, P3341, DOI 10.1128/JCM.40.9.3341-3345.2002
- de Sanjose S, 2002, VIRUS RES, V89, P201, DOI 10.1016/S0168-1702(02)00189-2
- Aynaud O, 1998, SEX TRANSM INFECT, V74, P32
- Franco EL, 1999, J INFECT DIS, V180, P1415, DOI 10.1086/315086
- Giuliano AR, 2008, CANCER EPIDEM BIOMAR, V17, P2036, DOI 10.1158/1055-9965.EPI-08-0151
- Critchlow CW, 1998, AIDS, V12, P1177, DOI 10.1097/00002030-199810000-00010
- Gomousa-Michael M, 2000, ACTA CYTOL, V44, P305
- BREESE PL, 1995, SEX TRANSM DIS, V22, P7, DOI 10.1097/00007435-199501000-00002
- Sirera G, 2006, AIDS, V20, P1201, DOI 10.1097/01.aids.0000226963.10342.f4
- Dunne EF, 2006, J INFECT DIS, V194, P1044, DOI 10.1086/507432
- Chin-Hong Peter V, 2005, Dermatol Ther, V18, P67, DOI 10.1111/j.1529-8019.2005.05009.x
- Cuthill S, 1995, J REPROD MED, V40, P823
- *IARC, 2007, MON EV CARC RISKS HU, V90, P179
- Koutsky Laura, 1997, American Journal of Medicine, V102, P3
- Lajous M, 2005, CANCER EPIDEM BIOMAR, V14, P1710, DOI 10.1158/1055-9965.EPI-04-0926
- Palefsky JM, 2003, J NATL CANC I MONOGR, P41
- Rezza G, 1997, EUR J EPIDEMIOL, V13, P937